PFS vs OS: What Is the Difference in Cancer Trials?

PFS and OS are two of the most important endpoints in oncology drug development.

PFS stands for progression-free survival.

OS stands for overall survival.

Both measure time, but they answer different questions.

What is OS?

Overall survival measures how long patients live from a defined starting point, such as randomization or treatment start, until death from any cause. OS is considered one of the strongest endpoints in cancer trials because it measures the outcome that matters most: survival.

What is PFS?

Progression-free survival measures how long patients live without the disease getting worse. A PFS event is usually tumor progression, relapse or death.

PFS can be useful because it occurs earlier than OS. That allows companies to run shorter trials and detect drug activity sooner.

Why PFS can be easier to achieve than OS

A drug may delay progression without extending life. This can happen if later-line therapies after progression are effective, control-arm patients receive strong salvage therapy, crossover is allowed, PFS benefit is small, toxicity offsets benefit or progression assessments are subjective.

Why PFS can be controversial

PFS depends on how progression is measured. In solid tumors, progression is often assessed using imaging scans. Scan timing, investigator assessment and open-label design can affect results.

PFS is useful, but investors should ask whether it is robust and clinically meaningful.

When PFS matters a lot

PFS can be very important when OS takes too long to measure, crossover makes OS hard to interpret, disease progression causes major symptoms, the PFS effect is large and durable, or regulators accept PFS as a basis for approval.

When OS matters more

OS is especially important when the disease is life-threatening, multiple prior therapies exist, PFS is subjective, the drug has toxicity concerns, the treatment effect is modest or regulators want definitive evidence.

What if PFS improves but OS does not?

This can still be valuable, but it depends on the disease and magnitude of benefit. A drug with strong PFS benefit, good safety and quality-of-life improvement may still be clinically useful even without OS benefit. But a small PFS benefit with no OS improvement may disappoint investors.

What if OS improves but PFS does not?

This is unusual but possible. It can happen because of delayed immune effects, post-progression benefit, statistical noise, small sample size, baseline imbalances or differences in subsequent therapy.

Frequently asked questions

What is the difference between PFS and OS?

Progression-free survival (PFS) measures how long patients live without the disease getting worse, while overall survival (OS) measures how long they live from a defined starting point until death from any cause. PFS asks how long the disease stayed controlled; OS asks how long patients actually lived. OS is generally considered the more definitive endpoint in oncology.

Why is PFS often easier to achieve than OS?

PFS events occur earlier, so trials can be shorter and can detect drug activity sooner. A drug can also delay progression without extending life, for example if effective later-line therapies, crossover, or strong salvage treatment help control-arm patients after progression. PFS can additionally depend on scan timing and subjective assessment of progression, which OS does not.

Is a drug still valuable if PFS improves but OS does not?

It can be, depending on the disease and the size of the benefit. A large, durable PFS gain with good safety and quality-of-life improvement may be clinically useful even without an OS benefit. But a small PFS improvement with no OS gain often disappoints investors, especially in life-threatening diseases where survival is the priority.

Bottom line

PFS asks: How long did the disease stay controlled?

OS asks: How long did patients live?

For biotech investors, OS is often the more definitive endpoint, but PFS can still be important depending on the setting.